Results 71 to 80 of about 1,716,661 (233)

Membrane‐Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors

open access: yesAdvanced Materials, EarlyView.
Membrane‐bound multimodal transducers enable longitudinal ultrasound‐guided photoacoustic monitoring and in situ thermal control of CAR T cells in heterogeneous solid tumors. Imaging correlates T cell trafficking with tumor response, distinguishing responders from nonresponders.
Myeongsoo Kim   +14 more
wiley   +1 more source

Advances in CAR-T therapy for central nervous system tumors

open access: yesBiomarker Research
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue ...
Delian Zhou, Xiaojian Zhu, Yi Xiao
doaj   +1 more source

Chimeric Antigen Receptor-T Cell Therapy

open access: yesHemaSphere, 2018
. Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR.
Jochen Buechner   +4 more
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao   +5 more
doaj   +1 more source

Photoacoustic Nanotagging for In Vivo Tracking and Optimization of Macrophage Immunotherapy in Solid Tumors

open access: yesAdvanced Materials, EarlyView.
Macrophage‐based immunotherapy for solid tumors is limited by poor tracking of cell localization and persistence. This study introduces nanotagged macrophages enabling near‐infrared photoacoustic imaging for real‐time monitoring. IFNγ‐conjugated tags enhance antitumor polarization without harming viability.
Seoyoon Song   +8 more
wiley   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

open access: yesCancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Modulation of miR‐23b Wnt/β‐catenin Axis Strengthens Endothelial Barrier Properties

open access: yesAdvanced Science, EarlyView.
Early blood‐brain barrier (BBB) disruption contributes to stroke and CNS disease pathology. miR‐23b was identified as a regulator of BBB integrity in brain endothelial cells. Inhibition of miR‐23b enhanced barrier‐associated properties, promoted repair‐related signaling, and reduced BBB leakage in experimental stroke models, supporting further ...
Victor Anthony Martinez   +16 more
wiley   +1 more source

Chimeric antigen receptor-natural killer

open access: yesJournal of Bone Marrow Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR) technology has transformed adoptive cell therapy, particularly through the success of CAR-T cells in hematologic malignancies.
Larissa Cardoso Zanetti   +2 more
doaj   +1 more source

Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities

open access: yes, 2020
Chimeric antigen receptor T cell therapies for thoracic cancers— challenges and ...
Slaney, CY   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy